

FETAL NUCHAL TRANSLUCENCY AND NASAL BONE SCREENING IN MULTIPLE PREGNANCIES

Giovanni Monni, Maria Angelica Zoppi, Carolina Axiana

Department of Obstetrics and Gynecology, Prenatal and Preimplantation Genetic Diagnosis,
Fetal Therapy, Ospedale Microcitemico Cagliari, Italy
prenatalmonni@tiscali.it

Multiple pregnancies, mostly if obtained by assisted reproduction techniques, are at higher risk for chromosomal defects, because of the advanced maternal age, but at same time, as these pregnancies are precious to the parents, and there is no resolute acceptance of the need of invasive prenatal diagnosis procedures, which are more difficult to perform and more hazardous for fetuses than in singleton pregnancies. Therefore non- invasive screening test for chromosomal abnormalities in multiple pregnancies are more acceptable.

Maternal serum biochemistry for trisomy 21 in multiple pregnancies has been proposed but it may be difficult to interpretate because of the interference between the serum marker concentrations and assisted reproductive drugs, and because of the overlap of biochemical markers measures from each fetus.

Multizygotic pregnancies originate from the fertilization of two or more oocytes by two or more spermatozoa, and present multichorionic placentation, while monozygotic pregnancies present monochorionic placentation in about 2/3 of cases.

Prenatal diagnosis of chorionicity can be made by ultrasound in the first trimester, as at 5 weeks gestation the number of sacs indicates the number of placentas (monochorionic, dichorionic, trichorionic etc.). As the gestation proceeds, the septum between the sacs become thinner, and only a triangular structure, the "lambda sign" remains at 10 to 14 weeks, in multichorionic pregnancies, while in monochorionic pregnancy there is no chorionic tissue between the two-amniotic sacs, the "T sign".

Monochorionic pregnancies are at higher risk than dichorionic pregnancies of prenatal and perinatal problems, as they are monozygotic, and because of the occurrence of specific problems due to transplacental circulation imbalance (twin-to-twin transfusion syndrome).

For multiple pregnancies derived from multizygotic conception, discordant karyotypes are expected. Prenatal sonographic estimation of zygoty is fundamental in the process of risk calculation. In a monochorionic pregnancy monozygoty can be supposed, and an equal risk for trisomy 21 for both fetuses, similar to the maternal age- related risk, can be calculated. The risk for the pregnancy of having one fetus with trisomy 21 is calculated by the sum of the risk for each fetus.

Ultrasound screening for trisomy 21 by first trimester nuchal translucency measurement is valid in twin and multiples. The test gives an individual risk for each fetus, and its accuracy is comparable to singleton pregnancies. NT measurement can be used in high order multiple pregnancies, and in those cases obtained by assisted reproductive technologies, because no evident difference has been found in the rate of enlarged nuchal translucency than in spontaneous multichorionic pregnancies.

In multiple pregnancies, the absence of nasal bone visualization, which is another accurate soft marker for trisomy 21 in the first trimester, can be used with the same efficiency as in singleton pregnancies. About 70% of trisomies 21 and an important percentage of other chromosomal abnormalities as trisomy 18 and 13, 45, X0, can manifest the sign of the absent nasal bone at ultrasound examination performed at 11- 14 weeks.

A higher rate of enlarged nuchal translucency has been described in monochorionic pregnancies.

In monochorionic diamniotic pregnancy, an enlarged nuchal translucency could be caused by placental circulation problems, rather than chromosomal abnormalities. This early imbalance of fluids between the fetuses can anticipate in the first trimester the inter-twin-to-twin transfusion, that manifest the most important diagnostic sign only after 16 weeks.

In multifetal pregnancies, when the number of fetuses is high, embryoreduction is usually performed in the first trimester. The choice as to which fetus to reduce is based fundamentally on technical considerations. It was proposed to offer invasive prenatal diagnosis for karyotype by chorionic villus sampling before performing embryoreduction. Because of the difficulties and costs of such invasive prenatal diagnosis in multiples, this approach has not been universally approved and it has been proposed to offer the nuchal translucency screening before embryo reduction. In fact the finding of an enlarged nuchal translucency, allowing the possibility to calculate the individual risk for trisomy in each fetus, can identify cases at higher risk for chromosomal abnormalities and for structural malformation in multiple pregnancies.

The presence of an enlarged NT is associated with an increased rate of chromosomal abnormalities, but moreover the risk for structural malformations and mostly cardiac defects in fetuses with normal karyotype is increased.

References

1. Cicero S, Curcio P, Papageorghiou A, Sonek J, Nicolaides KH. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study. *Lancet* 2001; 358: 1665-7.
2. Maymon R, Dreazen E, Tovbin Y, Bukovsky, Weinraub Z, Herman A. The feasibility of nuchal translucency measurement in higher order multiple pregnancies achieved by assisted reproduction. *Hum Reprod* 1999; 14: 2102-2105.
3. Meschede D, Lemcke B, Stussel J, Louwen F, Horst J. Strong preference for non- invasive prenatal diagnosis in women pregnant through intracytoplasmic sperm injection. *Prenat Diagn* 1998; 18: 700-705.
4. Monni G, Zoppi MA, Ibba RM, Floris M. Fetal nuchal translucency test for Down's syndrome. *Lancet* 1997; 350: 1631.
5. Monni G., Cau G, Lai R, Demontis G, Usai V. Intracytoplasmic sperm injection and prenatal invasive diagnosis. *Prenat Diagn* 1999; 19: 389-390.
6. Monni G, Ibba RM. Invasive procedures in multiple pregnancies. In : Weiner S, Kurjak A, editors. *Interventional Ultrasound*. New York- London: The Parthenon Publishing Group; 1999. p 105-115.
7. Monni G, Zoppi MA, Cau G, Lai R, Baldi M. Importance of nuchal translucency in multifetal pregnancy reduction. *Ultrasound Obstet Gynecol* 1999; 13, 377-378.
8. Monni G, Zoppi MA, Ibba RM, Putzolu M, Floris M. Nuchal translucency in multiple pregnancies. *Croat Med J*. 2000; 41: 266-9.
9. Monni G, Zoppi MA, Ibba RM. Absence of nasal bone and detection of trisomy 21. *Lancet* 2002; 359: 1343.
10. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. Fetal nuchal translucency screening for chromosomal defects in first trimester of pregnancy. *Br Med J* 1992; 304: 867-869.
11. Nicolaides KH, Sebire NJ, Snijders RJM, Souka AP. *The 11- 14 week's scan book*. London, UK: Parthenon Publishing, 2001.
12. Pandya PP, Hilbert F, Snijders RJM, Nicolaides KH. Nuchal translucency thickness and crown- rump length in twin pregnancies with chromosomally abnormal fetuses. *J Ultrasound Med* 1995; 14: 565-568.
13. Rodis JF, Egan JFX, Craffey A, Ciarleglio L, Greenstein RM, Scarza W. Calculated risk of chromosomal abnormalities in twin gestations. *Obstet Gynecol* 1990; 76: 1037-1041.
14. Sebire NJ, Snijders RJM, Hughes K, Sepulveda W, Nicolaides KH. Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10- 14 weeks of gestation. *Br J Obstet Gynaecol* 1996; 103: 999-1003.
15. Sebire NJ, D'Ercole C, Hughes K, Carvalho M, Nicolaides KH. Increased nuchal translucency thickness at 10-14 weeks of gestation as a predictor of severe twin-to-twin transfusion syndrome. *Ultrasound Obstet Gynecol*. 1997;10: 86- 9.
16. Sepulveda W, Sebire NJ, Hughes K, Odibo A, Nicolaides KH. The lambda sign at 10-14 weeks of gestation as a predictor of chorionicity in twin pregnancies. *Ultrasound Obstet Gynecol*. 1996;7: 421- 3.
17. Sepulveda W, Sebire NJ, Odibo A, Psarra A, Nicolaides KH. Prenatal determination of chorionicity in triplet pregnancy by ultrasonographic examination of the epsilon zone. *Obstet Gynecol*. 1996; 88: 855- 8.
18. Snijders RJM, Nicolaides K. *Ultrasound markers for chromosomal defects*. London, UK: Parthenon Publishing, 1996.
19. Souka AP, Snijders RJ, Novakov A, Soares W, Nicolaides KH. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10- 14 weeks of gestation. *Ultrasound Obstet Gynecol* 1998; 11: 391- 400.
20. Zoppi MA, Ibba RM, Axiana C, Floris M, Manca F, Monni G. Absence of fetal nasal bone and aneuploidies at first trimester nuchal translucency screening in unselected pregnancies. *Prenat Diagn*. 2003; 23: 496- 500.

Nuchal translucency is the normal fluid-filled subcutaneous space identified at the back of the fetal neck during the late first trimester and early second trimester (11 weeks 3 days to 13 weeks 6 days). It should not be confused with the nuchal...
Increased nuchal translucency is thought to be related to dilated lymphatic channels and is considered a nonspecific sign of more generalized fetal abnormality. Measurement of the nuchal translucency requires specific and standardized assessment and careful attention to technique.
Associations. Thickening of the nuchal translucency can be associated with a number of anomalies, including
pregnancy-associated plasma protein A (PAPP-A). estriol/estriol. Nuchal translucency scan. Preeclampsia screening. Nasal bone. Ductus venosus flow. Tricuspid flow.
Assessment: Nuchal translucency. Performance audits. Mean arterial pressure. Uterine artery PI. Nuchal translucency. Ductus venosus PIV. Serum sFLT-1.
Fetal abnormalities
» Multiple pregnancies. MC twins: death of one fetus. Prevalence
A nuchal translucency scan (NT scan) is an ultrasound screening test for assessing whether your baby is likely to have Down's syndrome. Find out what it means for you and your baby. - BabyCentre UK.
Nuchal translucency is a collection of fluid under the skin at the back of your baby's neck. The amount of fluid is measured during a nuchal translucency (NT) ultrasound scan: between 11 weeks and 14 weeks of pregnancy. or when your baby measures between 45mm (1.8in) and 84mm (3.3in) (Nicolaides 2011, FASP 2015, UK NSC 2016).
2016. The UK NSC recommendation on Down's syndrome screening in pregnancy UK National Screening Committee. legacyscreening.phe.org.uk [Accessed July 2017]. Show references Hide references. Track your baby's development.